Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Amongst sufferers domestically superior, unresectable, stage 3 non-small cell lengthy most cancers (NSCLC) that has not progressed after platinum-based concurrent chemoradiation (cCRT),...
Sufferers with beforehand handled, regionally superior or metastatic hormone receptor (HR)-positive, HER2-negative breast most cancers skilled superior progression-free survival when handled with...
Amongst sufferers with high-risk, HER2-positive early breast most cancers, presurgical, or neoadjuvant, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) adopted by paclitaxel, Herceptin...
Amongst sufferers with high-risk cutaneous squamous cell carcinoma (CSCC), postsurgical therapy with Libtayo (cemiplimab-rwlc) has been discovered to be related to an...
